Viewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition.
Brian Carlin
Advertisement
Brian Carlin is director QbD/Regulatory, DFE Pharma US
Articles by Brian Carlin
Advertisement
Latest Updated Articles
Understanding Concomitant Components in Pharmaceutical ExcipientsPublished: February 3rd 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The Regulatory Crucible: Risk, Resource Drain, and the Hidden Trade-Offs of the CNPV Pilot Program
2
Leveraging AI/ML to Reduce Risk in Drug Development: Part One
3
Molecular Dynamics and Quantum Calculations: AAPS Thermo Fisher Interview, Part Two
4
New Targets for Clinical Trials in the European Union
5
